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Abstract 
Herpesviruses are divided into the α, β and γ subfamilies. More than 90% of the human 
population carries at least one, and more often a combination of several latent 
herpesviruses. Latency is the ability of a virus to silently persist in the host, and to 
reactivate upon episodes of immune suppression. During latency, the immune system is 
weakly, but persistently stimulated by viral antigens, and the effects of such burden on 
the homeostasis and function of the immune system remain unclear. To address this 
question, mice were infected with α, β or γ herpesviruses, individually or in 
combinations. There were no obvious changes in the homeostasis of the B cells, but an 
irreversible and very large increase of activated CD8 T cells, especially in mice carrying 
latent mouse cytomegalovirus (MCMV), a β herpesvirus. To investigate if this change 
led to functional impairments of the immune response to a new infection, the latently 
infected mice were challenged with vesicular stomatitis virus (VSV).  At day 7 or 14 post 
challenge, the number of CD8 T cells responding to a VSV antigen were not altered, but 
due to the huge increase in the size of the CD8 compartment, the fraction of VSV-
responding cells was reduced in the blood (but not in lymphatic organs) of mice carrying 
latent MCMV. Latent herpesviruses did not affect the VSV responses in the CD4 T cell 
compartment, but there was a delay in the Immunoglobulin (Ig) class-switch in MCMV 
infected mice. In conclusion, infection with persistent herpesviruses resulted in 
permanent changes in the homeostasis but not the function of the T cells and in delayed 
Ig class-switch in MCMV infected mice. Due to the pervasiveness of latent herpesvirus 
infections, these results may have important implications for public health, but also for 
the design of CMV-based vaccines.  
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Chapter 1 
1.0 Introduction 
1.1.1 Herpesviruses  
The family Herpesviridae is, according to the International Committee on Taxonomy of 
Viruses (ICTV), divided into three sub-families, Alphaherpesvirinae (Varicellovirus, 
Simplexvirus, Mardivirus and Iltovirus genera), Betaherpesvirinae (Cytomegalovirus, 
Roseolovirus and Muromegalovirus genera), and Gammaherpesvirinae (Rhadinovirus 
and Lymphocryptovirus genera). All members of the family Herpesviridae have a 
spherical morphology and are made up of four major components, namely: the 
envelope, the tegument, the capsid and the core (1, 2) (Figure 1.1). Herpesviruses have 
linear double stranded DNA with genome size between 125 and 240 kilobase (kb) 
encased in an icosahedral-shaped nucleocapsid. All members of Herpesviridae 
replicates their genome in the host cell nucleus and express their genes in a specific 
order,  where the immediate-early (IE) genes (encoding regulatory proteins and 
transcription factors) are expressed first, then early genes which encode proteins 
necessary for DNA replication, and lastly the late genes, which encode structural 
proteins (2). IE genes are resistant to cycloheximide (CHX) treatment (a protein 
synthesis inhibitor) in contrast to early genes which are sensitive to CHX, but are 
resistant to phosphonoacetic acid (PAA) treatment (a DNA polymerase inhibitor). Late 
genes are sensitive to both CHX and PAA, enabling selective distinction of the gene 
classes by western and northern blot analysis (3-6). Herpesviruses can infect mammals, 
reptiles, birds, amphibians and fish. In humans, primary infection may cause mild to 
severe disease upon which the viruses persist in the host for life in the latent phase. 
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Latency is defined as the maintenance of the viral genome in host tissues in the 
absence of infective viral particles, as detected by conventional virological assays. CMV 
reactivation from latency is one of the main causes of morbidity and mortality among 
immunocompromised hosts, for instance among bone marrow/solid organ transplant 
recipients or acquired immunodeficiency syndrome (AIDS) patients. Shedding of the 
viruses is done mostly through saliva, and while other routes of shedding are not as 
common, they are still possible, for instance through genital and other secretions. The 
vast majority of people carry herpesviruses in various combinations. Most people are 
positive for varicella, herpes simplex, cytomegalovirus and/or Epstein - Barr virus (7).   
 
Figure 1.1: The four major components of herpesviruses 
 
1.1.2 Latent infection with herpesviruses versus other chronic infections: Human 
immunodeficiency virus (HIV) 
Both herpesviruses and HIV cause persistent infection and both may lead to disease 
progression once the host’s immunity is compromised, but there are important 
differences. In HIV, the replication is active after the acute phase is cleared, and hence 
Envelope
Tegument
Capsid
DNA core
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the viral antigens constantly stimulate the immune system. Herpesviruses enter into a 
quiescent state after the acute phase with a low level of viral antigens exposed to the 
immune system (8) (Figure 1.2). HIV constantly stimulates the T cells, which may 
cause their exhaustion (9).This differs from the periodic stimulation of the immune 
system by latent herpesviruses, which may experience dormancy and reactivation 
cycles during latency (10). A long-term association of the herpesviruses and their 
natural host is speculated to have caused evolutionary adaptations in both the virus and 
the host, which favor a détente, where viruses do not harm the host, while not being 
attacked by the host’s immune system.   
 
 
 
Figure 1.2: Persistent viruses and their antigenic load over time (adapted from (8))  
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1.2 Activation of the immune system by pathogens  
The immune system consists of adaptive and innate immunity. Innate immunity is 
considered the first line of defense against pathogens and responds with the same 
magnitude upon a re-encounter of the same antigen, whereas adaptive immunity 
requires more time to respond, but has faster and more robust secondary responses 
when the same pathogen re-infects the host (11). The Adaptive immunity is mediated by 
two cellular compartments: the cell mediated immunity, which is mediated by αβ T 
lymphocytes and the humoral immunity which is based on the antibodies produced by 
plasma cells differentiated from B-cells. Cell mediated immunity deals predominantly 
with intracellular pathogens, whereas humoral immunity protects us against both 
intracellular and extracellular pathogens and their toxins. Furthermore, T cells are 
divided into helper (Th) and cytotoxic T lymphocytes (CTL), characterized by the 
surface expression of CD4 or CD8 receptors, respectively. Th lymphocytes, also 
referred to as CD4 T cells, exert their effects by helping either B cells or CTL (also 
known as CD8 T-cells), whereas CTL have a direct cytotoxic effect on their target. The 
cells that mediate innate immunity are natural killer cells and cells of the myeloid lineage 
including monocytes, granulocytes, macrophages, all phagocytic cells, eosinophils and 
basophils. Other cells of the immune system that appear not to fit clearly into either 
category, because they are at the intersection of the innate and adaptive immunity 
include gamma delta T (γδ T) cells and NKT cells (12, 13). In order to confer strong 
protective immunity against pathogens, the innate and the adaptive immune system 
work together but more details on how the innate immunity, γδ T cells, and NKT cells 
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are activated and respond to pathogens are not discussed here as it is beyond the 
scope of this study. 
1.2.1 Activation of CD8 T cells  
When viruses infect cells, some of the newly synthesized viral proteins are tagged by 
ubiquitin and degraded by proteasomes into small peptides, which are then transported 
into the endoplasmic reticulum and loaded onto the major histocompatibility complex-1 
molecules (MHC I) expressed by all nucleated cells. The peptide-MHC I complexes are 
transported to the surface of the infected cell and presented to the CD8 T cells (14). 
Naïve T cells are activated in the secondary lymphoid organs. The migration of the 
naïve T cells into the lymph node is mediated by receptor molecules (CD62L and 
CCR7) expressed on their surface, which allow naïve cell homing to lymph nodes. 
Naïve CD8 T cells are activated by recognizing their cognate antigen (in this case a viral 
peptide-MHC I complex on the surface of the dendritic cells) with their TCR and by 
simultaneous binding of the co-stimulatory receptor (CD28) to their ligands on activated 
dendritic cells (CD80/CD86). The activation results in T-cell expansion and 
differentiation into effector cells (15). Effector cells are armed with cytotoxic granules 
(granzymes) and perforins which allow them to kill target cells. In addition, they can kill 
the target cell by the interaction of their FAS-ligand with the FAS receptor expressed on 
the surface of infected cells. Furthermore, effector cells can produce inflammatory 
cytokines such as TNFα and IFNγ, which have the potential to block viral replication 
either by killing infected cells or by repressing the viral gene expression. After activation, 
effector CD8 T cells loose CD62L and CCR7 from their surface which allows them to 
migrate out of the draining lymph node. Instead a new pattern of cell adhesion 
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molecules (CD11a, CD44) and chemokine receptors (CCR5, CXCR3) is expressed on 
their cell surface, which mediates their migration towards sites of inflammation and 
infection, where they may exert their cytotoxic effect on the virus-infected cells (16-18). 
Moreover, activated cells are characterized by the loss of expression of defined cytokine 
receptors at the surface such as the IL-7 receptor α chain (CD127), or the IL-15/IL-2 
receptor β chain (CD122) (15, 19). Upon clearance of an infection, approximately 90% 
of effector T cells die by apoptosis leaving out about 10% of them which are then 
differentiated into memory cells which re-express the lymph node homing markers, but 
maintain the surface expression of adhesion markers that are typical of primed cells 
(CD11a, CD44) (15, 20). 
1.2.2 Activation of CD4 T cells  
CD4 T cells are classically divided into Th1 and Th2 T helper subsets. The non-classical 
subsets includes T-helper 17 (Th17), follicular helper T cells (Tfh) and regulatory T cells 
(Tregs). All the T helper subsets are defined by distinct cytokine secretion patterns. Th1 
cells are typically involved in the host defense against intracellular pathogens such as 
viruses, whereas Th17 secrete cytokines (IL-17, IL-22) that recruit neutrophils to the site 
of infection and control extracellular pathogens such as bacteria and fungi. Th2 cells 
also function to defend the host against extracellular pathogens such as helminthes 
infection (21, 22). Tfh cells are found in the lymphoid tissues and they mediate humoral 
immune response by their interaction with the B cells (23, 24). Tregs suppress the 
immune function by secreting anti-inflammatory cytokines (IL10 and TGFβ) (25).  Upon 
activation, Th1 cells can either directly kill the virus infected cells, by producing TNFα, 
which interacts with the TNF receptor p55 on the surface of infected cells and results in 
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caspase-dependent apoptosis, or they can produce Th1 cytokines (TNFα and IFNγ) 
which activate macrophages (26-29). CD4 T cells are activated by recognizing 
immunogenic peptides on the surface of professional antigen presenting cells (dendritic 
cells) in the context of the MHC II molecules.  Peptides that are loaded on MHC II 
molecules are derived from proteins (host or viral), which are degraded in the 
endosomes by proteolytic enzymes, and therefore may be acquired by endocytosis from 
surrounding cells. As in the case of MHC I restricted peptides, the dendritic cells migrate 
to the lymph node to present MHC II peptides to naïve CD4 T cells, which are thus 
activated, essentially in the same manner as CD8 T cells  (14, 30). CD4 T cells express 
surface molecules which closely match those on CD8 T cells, and enable them to 
migrate to and from the secondary lymphoid organ to the site of infection. In addition 
activated CD4 T cells up-regulate CD40L which in turn binds CD40 on the dendritic cells 
and up-regulates the MHC expression and the expression of co-stimulatory (CD80 and 
CD86) molecules on the surface (31-33). Activated CD4 T cells expand and differentiate 
into effector cells, whose numbers contract upon the clearance of the infection, mainly 
by apoptosis. A small fraction (about 10%) of effector cells typically remains and 
differentiates into memory cells.   
1.2.3 Activation of B cells  
B cells are produced in the bone marrow and then migrate to the secondary lymphoid 
organs. Activation of the B cells by antigens starts in the B cell zones of secondary 
lymphoid organs. During this process, naïve B cells through their B cell receptor (BCR) 
recognize the antigen, internalize, process and then load it onto MHC II molecules. 
These partially activated B cells migrate to the T and B cell zone border and interact 
Introduction 
9 
 
with follicular CD4 T cells. This process leads to an expansion of the B cells, formation 
of the germinal center as well as differentiation of B cells into memory cells and 
antibody secreting plasma cells (34, 35). Simultaneously, the immunoglobulin isotype 
switches. The constant region of the BCR changes from IgM and IgD to IgG, IgA or IgE 
(36). The activated and expanded B cells in the germinal center undergo a selection 
process in which the clones with low affinity BCRs for the antigen die by apoptosis, 
leaving predominantly high affinity clones, which can be recruited into the memory pool. 
Upon re-infection with the same pathogen, memory cells differentiate immediately into 
plasma cells that secrete high-affinity antibodies that are specific for the pathogen.  
Antibodies can neutralize toxins and free viruses, hence preventing their dissemination. 
Antibodies are also responsible for opsonization of pathogens, tagging them for 
phagocytosis and enzymatic digestion by macrophages. The ability of old individuals to 
mount a robust humoral immunity upon  infection or vaccination is lower than in young 
ones, mainly due to the decline in the formation and function of the germinal center (37, 
38). It is not clear whether adult hosts infected with single or multiple persistent 
herpesviruses have more pronounced deterioration in the function of the B cell 
compartment than their non-infected counterparts and if the effect is more pronounced 
with one type of herpesvirus than the others.    
1.2.4 Immune aging  
Immune aging (also called immunosenescence) is the loss of the immune function, 
coupled to an increase in inflammatory conditions which occurs in old age.  Hallmarks of 
immunosenescence include the reduction of the number of newly generated naïve cell 
in the thymus caused by its involution, while the number of differentiated and terminally 
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differentiated T cells increases (39, 40). Immunosenescence should not be confused 
with the immune risk phenotype (IRP), where the latter is a set of alterations in the T cell 
compartment of elderly people which are predictive of significantly shortened life 
expectancy. Individuals with IRP have an inverted CD4/CD8 ratio, poor proliferative T-
cell responses to polyclonal Ag stimulation and an increase in the absolute count of T 
cells with CD45RA+ CD28- CD27- CD57+  phenotype (41, 42).  
Whereas the global improvement of socioeconomic conditions has improved the life 
expectancy of people, leading to a dramatic increase in the population of people who 
are aged 60 years and above, immunosenescence predisposes them to suffer or even 
die from emerging infections. Therefore, it is important to understand the factors that 
may accelerate or slow the onset of immunosenescence and suggest measures that 
may improve the lives of the elderly.  Due to practical consideration, the majority of 
human studies on immunosenescence have relied on cross-sectional comparison of 
young and elderly adults. Longitudinal studies are more feasible in animal models, 
especially in animals which have a short life span, such as mice with a life span of up to 
three years. Experiments in primates, allow the acquisition of data from animal species 
which are closely related to humans and therefore bear highly relevant information, yet 
are constrained by the relative length of the life-span in most non-human primates. 
A study in aged mice has associated the decline in CD8 T-cell immune responses to 
influenza to the decline in T cell repertoire (TCR) diversity in the naïve CD8 pool. Since 
thymectomized young mice had similar negative effects as aged mice, these data 
suggested that the involution of the thymus is a plausible cause of the decline in naïve T 
cell repertoire diversity (43). Experiments in rhesus monkeys infected with modified 
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vaccinia Ankara strain (MVA) also showed poor CD8 T-cell responses in aged 
monkeys, and an association to the loss of naïve CD8 T cells and constriction in the 
TCR repertoire diversity (44). Other studies have shown that recent thymic emigrants 
(RTEs) and CTL from aged mice respond poorly to stimulation and produce less IL2 as 
compared to those from the young mice suggesting that cell intrinsic defects of naïve T-
cells may also contribute to immunosenescence (45, 46). The B cell compartment is 
also affected by the aging process, which is manifested as the decline in ability of 
follicular CD4 T cells in the germinal center to provide a cognate T-cell help and 
subsequent reduced ability of B cells to undergo class-switch recombination, the 
process which is crucial for an effective and robust humoral response (47).   
Cytomegalovirus infection has been proposed as a contributor to immunosenescence. 
Studies in human and murine systems have shown that thymectomized, CMV infected 
young host have premature immune aging, when compared to CMV negative (48, 49). 
This suggests that persistent antigenic stimulation of hosts with no functional thymus 
and small populations of naïve cells (such as old individuals) may increase the 
susceptibility to new infections and reduce the T-cell response to vaccinations, as 
observed in the aged hosts (48, 50).   
It remains unclear whether the effect of CMV infection on the ability of the 
immunosenescent host to respond to a new infection would be more pronounced in 
hosts primed with the persistent virus at a young age, or in those primed at a later time 
in the adult age. Moreover, it is not clear whether herpesviruses from other sub-families 
accelerate immunosenescence in the same way as it has been described in CMV 
infection.  
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1.3 Modulation of the adaptive immunity by α-herpesviruses: Herpes simplex 
virus type 1 (HSV-1) 
Herpes simplex virus is a ubiquitous virus that naturally infects humans. The 
seroprevalence of HSV in the adult population is between 60-95% worldwide (51-53). 
Upon infection, the virus activates CD8 T cells that clear the primary infection and 
generate memory cells. HSV-1 establishes latency in the sensory ganglia and in the 
central nerve system (CNS). HSV-1 infection may cause fever and fever blisters during 
the acute phase and reactivation from latency. Reactivation of the virus may occur in 
immunocompromised individuals or can be induced when an individual is under physical 
or emotional stress during which the virus migrates from the site of latency into the 
periphery (54-56). 
In vivo studies on alpha-herpesviruses are done on HSV-1 because the virus can 
readily infect mice as compared to other common alpha-herpesviruses infecting humans 
such as HSV-2 and varicella zoster. Studies in the mouse model have shown that 
systemic HSV-1 infection of C57BL/6 mice causes an accumulation of CD8 T cells 
specific for a peptide (SSIEFARL) derived from glycoprotein B (gB) with a kinetic that is 
characterized by a progressive accumulation of these cells from day 45 post-infection 
(57). On the other hand, local infection with HSV-1 (ocular infection) resulted in low-
level maintenance of memory gB specific CD8 T cells after the contraction of the acute 
phase. Interestingly, the level of these cells were maintained at low level until 18 months 
post infection, but was then followed by a dramatic expansion, which resulted in cell 
counts of peptide specific cells which were higher than the initial peak value reached 
during the acute phase of infection (58). It remained unclear whether the expansion of 
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the gB specific CD8 T cells was due to weak control of the latent virus (perhaps caused 
by deterioration in the function of CD4 T cells or B cells) and reactive increase in the 
number of activated CD8 T cells in the old age. CD8 T cells specific for the HSV-1 gB 
peptide have a central memory phenotype in long term infected old mice 
(CD122+CD127+CD44+), which contrasts with MCMV specific CD8 T cells (discussed 
in detail in the next section)  (58). Moreover, the expanded populations of HSV1 specific 
CD8 T cells that express KLRG1 maintain their ability to proliferate when transferred 
into RAG1 knockout mice (59). In a recent study, Smithey et al., compared the effects of 
life-long MCMV and HSV-1 infection and found out that CD8 T cells responses to 
heterologous infection were comparable in both infections, but only mice infected with 
MCMV, alone or in combination with HSV-1, showed significantly impaired ability to 
control the novel infection (60).  
HSV-1 specific CD4 T cells have shown to be important for clearing HSV-1 in neural 
tissue in a manner that is independent of Fas/perforin (60). Another  study has shown 
that CD4 T cells help the gB specific CD8 T cells to control HSV-1, and that in absence 
of CD4 T cells the HSV-1 specific CD8 T cells expressed the inhibitory receptor PD-1 
(61). Since most of the studies in HSV-1 infection were focused on the CD8 T cell 
compartment, it remains unclear if the virus affects also CD4 and/or B cells. Finally, 
most of these experimental models have focused on HSV-1 infection in isolation, in 
absence of other herpesviral infections, although HSV-1 infection usually occurs in 
people that are infected with multiple herpesviruses. Therefore, the experimental 
infection with multiple herpes viruses may also offer insights to understand how 
herpesviruses may affect the adaptive immune system.  
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1.4 Modulation of the adaptive immunity by β-herpesviruses: Cytomegalovirus 
(CMV) 
Cytomegalovirus is a ubiquitous virus carried by 50% – 80% of the population in 
developed and 90 – 100% of people in developing countries (62, 63). Primary infection 
with the virus can cause fever or can also be asymptomatic. Congenital infection with 
CMV may cause birth defects such as hearing loss, blindness and learning disabilities in 
newborns. Moreover, reactivation of the virus from latency in immunocompromised 
hosts such as stem cell or organ transplant recipients on immunosuppressive therapy 
and AIDS patients may cause retinitis, pneumonitis, colitis, encephalitis and graft 
rejection (64, 65).  CMV is species specific, but viruses that coevolved with different 
species have very similar genomes and interact with similar facets of the immune 
system of their hosts. This allows the study of CMV pathogenesis and interaction with 
the host in animal models.  
Longitudinal studies in cohorts of aged people that focused on the effects of latent CMV 
on T cell immunity have shown an association between CMV seropositivity and 
phenotype changes in the T cell compartment (66-68). Infection with CMV has been 
proposed as one of the main environmental factor accelerating immunosenescence and 
changing the immune system towards IRP (68-73). Findings in the mouse model of 
CMV infection supported this hypothesis. Monitoring of MCMV  specific CD8 T cells 
over a long period of time showed  that there is an expansion of selected 
immunodominant epitopes, a phenomenon known as “memory inflation” (74-76). The 
inflated CD8 T cells keep the reactivation episodes of the virus in check and their 
accumulation suggests that, each reactivation episode may lead to recruitment of new 
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naïve T cells into the memory pool (77). It was shown that by replacing the IE1 
anchoring residue leucine with the alanine residue on the MCMV genome resulted into 
IE3 transcription and higher IE1 transcripts during latency, which suggested CD8 T cells 
were constantly suppressing the reactivation events by sensing the IE1 protein 
presented by MHCI molecules on the infected cells (78) 
We have recently published that mice infected with MCMV, but not with vaccinia 
exhibited a reduced frequency of CD8 T cells responding to a challenge with unrelated 
viruses (e.g. West Nile or flu virus). Furthermore, we have shown that the fraction of 
CD8 T cells responding to the challenge inversely correlates to the fraction of effector 
memory CD8 T cells (Figure 1.3). However, in this study we did not address the 
question whether the absolute numbers of these cells was also reduced.  
We proposed that the increase of the frequency of memory T cells with the late 
differentiated phenotype and the decrease of the frequency of naïve T cells in CMV 
infected hosts might impair the immunity to the challenge pathogen either because they 
lower the number of naïve T cells available for responding to novel infections, or (2) 
lead to a competition for immunological space.  
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Figure 1.3: Correlation between frequencies of CD8 T cells responding to West 
Nile virus and EM CD8 T cells in adult mice long-term infected with MCMV, VACV 
or nothing (mock). (Adapted from (79))  
 
Studies on CD4 T cell responses to human CMV have shown a negative correlation 
between the number of viral DNA copies and the number of CD4 T cells specific for the 
virus (80). Moreover, these cells showed a late differentiated phenotype (CD27-CD28- 
and short telomere), suggesting the involvement of CD4 T cells in the control of the 
virus (81). In the mouse model of CMV infection, CD4 T cells were shown to contribute 
to the inflation of CD8 T cells (82, 83). Monitoring of the kinetic of MCMV specific CD4 T 
cells by restimulation with a library of overlapping CMV peptides revealed no long-term 
accumulation of CMV specific CD4 T cells, but rather the maintenance of a stable 
number of  CD4 T cells after clearance of the  primary infection  (84). There are no 
available studies on the effect of latent CMV infection (alone or in combination with 
other infections) on the homeostasis and function of the peripheral CD4 pool. Results 
from Trzonkowski et al., suggested CMV infection was associated with elevated 
proinflammatory cytokines (TNFα, IL6, IL-1β) and low level of serum anti-hemagglutinin 
titers after influenza vaccination (85). However, these results were not supported by  
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another study from a Dutch cohort of elderly people in long-term care facilities where 
they found no association between CMV infection and poor responsiveness to influenza 
vaccination (86). Experiments in the mouse model showed that B cells are not 
necessary for the control of primary virus infection, but that MCMV disseminates much 
more efficiently upon reactivation in B cell deficient mice suggesting that the B cells play 
an important role in blocking virus dissemination upon reactivation (87). However, the 
effect of persistent herpesvirus infection on the phenotype of B cells and the quality of 
antibodies produced against new infections has not been studied.  
1.5 Modulation of the adaptive immunity by γ-herpesviruses: Epstein - Barr virus 
(EBV) / Murine herpesvirus-68 (MHV-68) 
Approximately 90% of adult people are estimated to carry EBV asymptomatically (88, 
89). Primary infection usually occurs during childhood through saliva contact and may 
be asymptomatic or, in some cases, may cause fever and lymphadenopathy (90, 91).  
Upon clearance of the primary infection, the virus establishes life-long latency in B cells. 
Reactivation from latency can occur in severely immunocompromised individuals.  
Moreover, EBV infection may cause Burkitt’s lymphoma, Hodgkin’s lymphoma or 
nasopharyngeal carcinoma (92) and therefore the virus was categorized as a 
‘carcinogenic agent’ by the world health organization in 1997 (93). Studies to 
understand pathogenesis and immunity against gamma herpesviruses utilize the 
established prototypic Murine gammaherpesvirus clone 68 (MHV-68, γHV68 or Murid 
herpesvirus-4), which is closely related to the Kaposi sarcoma-associated herpesvirus 
and EBV (94-96). The virus was isolated from the bank voles (Clethrionomys glareolus), 
its natural host (97), but it is well-able to infect laboratory mice (94, 98) and  establish 
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latency not only in the B cells as EBV, but also in the dendritic cells and macrophages 
(99, 100). 
CD8 T cells are important to control the acute phase of MHV-68 infection and to 
suppress reactivation of the virus from latency. Two well-characterized MHV-68 
immunodominant epitopes (ORF6 and ORF61) are commonly used to study CD8 T cell 
responses against MHV-68 in C57BL/6 mice. On the other hand, no inflationary MHV-
68 peptide has been identified so far, which differs from MCMV or HSV-1 infected (101).  
In humans carrying EBV, most of the EBV-specific CD8 T cells show a central memory 
phenotype and no sign of memory inflation except an accumulation of these cells in 
tonsils, at sites of latent infection (102).  
Studies on the function of CD4 T cells during MHV-68 infection have shown that these 
cells can suppress the virus replication independently of CD8 T cells and B cells (103, 
104). The suppression from reactivation and killing of virus-infected cells by CD4 T cells 
is mediated by IFNγ and direct cytotoxicity (105). It remains unclear, if the number of 
MHV-68 specific CD4 T cells increases over time. Similarly, the phenotypes of MHV-68 
specific memory CD4 T cells have not been described. Due to the fact that most people 
are EBV seropositive, it is difficult to determine if the presence of gamma-herpesviruses 
in the host may alter the functional capacity of the adaptive immune system to respond 
to emerging infections.   
1.6 Detection of phenotypic changes and functional capacity of the adaptive 
immunity 
Several markers on the lymphocyte subsets which are up-regulated or down-regulated 
upon infection have been identified by multi-parametric flow-cytometry of cells stained 
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with monoclonal antibodies against these markers. Furthermore, functional 
immunological assays allow the measuring of the size and the quality of the immune 
responses to antigens including, but not limited to, ELISPOT, ELISA in vitro and in vivo 
neutralization assays. In vitro antigenic restimulation followed by flow cytomety for 
intracellular cytokines or proliferation markers, allow the study of the immune phenotype 
and function.  
T cells that are specific for a certain epitope may also be detected in flow cytometry or 
FACS-sorted by peptide-MHC multimers coupled to fluorochromes (106, 107). 
Commonly used multimers include tetramers, pentamers and dextramers (108, 109), 
where the main difference between multimers is the type of their backbone, and hence 
the number of MHC-peptide monomers and fluorochromes they carry. Tetramers have a 
streptavidin backbone and contain four MHC-peptide complexes and one fluorochrome 
bound to it while pentamers are composed of a pentameric complex backbone that 
binds five MHC-peptides and five fluorochromes. Dextramers are composed of a 
dextran polymer backbone that carries large number of MHC-peptide complexes which 
increases the binding avidity of the complex to the surface of a T-cell, and thus 
enhances the detection of low avidity antigen specific T cells recognizing low avidity 
targets.  
The function of plasma cells derived from B cells is usually determined by the amount 
and quality of antibodies that are produced by them. While the ELISA assay is used to 
determine the physical concentration of antigen-specific antibodies in the serum, the in 
vitro neutralization assay allows the testing of their functional capacity (usually 
expressed as serum dilution that is still sufficient to neutralize the target virus.  
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In this study, the phenotype and the function of the adaptive immune system of mice 
infected with various herpesviruses were analyzed by a combination of multicolor flow-
cytometric analysis and in vitro neutralization assay.   
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Chapter 2 
2.0 Aim of the thesis 
Several recent in vivo studies showed that herpesviruses have the potential to 
irreversibly affect the adaptive immune system (49, 79, 110). The studies were focused 
on the CD8 T cell subset and identified life-long phenotypic changes in hosts carrying 
herpesviruses, like CMV or HSV-1. However, these studies focused on infections with 
one single herpesvirus in isolation and only on the T-cell compartment. While most 
people carry more than one type of herpesviruses, no study has compared the effects of 
single latent infection versus multiple infections with diverse herpesviruses in an 
experimental model, and no study addressed the effect of latent infections on cellular 
compartments beyond the CD8 T cells subset.  
The aim of this thesis was to determine, in a mouse model of infection, whether latent 
herpesvirus infections affect the adaptive immune system of adult hosts and if they alter 
immune responses to an unrelated viral infection.  
2.1 Specific objectives 
1. To dynamically monitor the long-term homeostatic changes in the CD8 T cell 
compartment of mice carrying latent viruses in isolation, or in combination. 
2. To determine the effects of the duration of the latent infection with α, β or γ 
herpesviruses (alone or in combination) on the ability of the adaptive immune 
system to respond to a new, unrelated infection.  
3. To compare the effects of latent herpesvirus infections on the CD4 T cell or B cell 
response to a new, unrelated infection. 
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Chapter 3 
3.0 Materials and Methods 
3.1 Materials 
3.1.1 Antibodies 
Antibody/Multimer Clone Supplier 
CD11a-PE-Cy7 2D7 BD, USA 
CD127-PE A7R34 Biolegend, USA 
CD25-APC PC61.5 eBioscience, Germany 
CD28 R1-2 eBioscience, Germany 
CD3-APC-eFluor780 17A2 eBioscience, Germany 
CD44-Alexa fluor700 IM7 Biolegend, USA 
CD44-FITC IM7 Biolegend, USA 
CD49d 37.51 eBioscience, Germany 
CD4-APC GK1.5 Biolegend, USA 
CD4-FITC RM4-5 eBioscience, Germany 
CD4-Pacific Blue GK1.5 Biolegend, USA 
CD62L-eFluoro 605NC MEL-14 eBioscience, Germany 
CD62L-FITC MEL-14 Biolegend, USA 
FoxP3-PE FJK-16s eBioscience, Germany 
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IFNγ-APC XMG1.2 Biolegend, USA 
KLRG1-Biotin 2F1/KLRG1 eBioscience, Germany 
NKG2A/C/E-FITC 20d5 eBioscience, Germany 
Nkp46-PE 29A1.4 Biolegend, USA 
Streptavidin-BV570 N/A Biolegend, USA 
TNFα-FITC MP6-XT22 Biolegend, USA 
VSV-dextramer-PE N/A Immudex, Denmark 
αCD8-PerCp-Cy5.5 53-6.5 Biolegend, USA 
 
3.1.2 Cell lines 
Cell line 
ATCC 
number 
Supplier 
BHK 21 CRL-13001 ATCC, USA 
M2-10B4 CRL-1972 ATCC, USA 
NIH3T3 CRL-1658 ATCC, USA 
Vero CCL-81 ATCC, USA 
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3.1.3 Chemicals 
Chemical/Reagent Supplier 
2-Mercaptoethanol Sigma-Aldrich Chemie, Germany 
Brefeldin A Sigma-Aldrich Chemie, Germany 
Crystal violet Serva, Germany 
Ethanol Fluka, Switzerland 
Fetal calf serum Greiner Bio-One, USA 
Formaldehyde Carl Roth, Germany 
Heparin Ratiopharm, Germany 
Isofluran Essex Tierarznei, Germany 
Ketamine CP-Pharma, Germany 
L-Glutamine Gibco, UK 
Methylcellulose Sigma-Aldrich Chemie, Germany 
Penicillin/Streptomycin Gibco, UK 
Sodium Chloride J.T Baker, The Netherlands 
Xylazine WDT, Germany 
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3.1.4 Buffers 
Buffer/Media Supplements  Company 
   
ACK 
1mM EDTA, 10mM 
KHCO3, 155mM 
NH4Cl, pH 7.3 
 
DMEM N/A Gibco, UK 
FACS 1xPBS, 5% FBS 
 
Fixation buffer N/A eBioscience 
Fixation/permeabilization 
buffer 
N/A eBioscience 
HBSS N/A Appli Chem, Germany 
PBS 
2.7 mM KCl, 1.8 
mM KH2PO4, 137 
mM NaCl, 10 mM 
Na2HPO4, pH7.4 
 
Permeabilization buffer N/A eBioscience 
RPMI 1640 N/A Gibco, UK 
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3.1.5 Peptides 
Peptide 
Haplotype 
specificity 
Sequence Reference Supplier 
HSV-1 gB H-2kb SSIEFARL (57, 111, 112) HZI, Germany 
MCMV IE1 (pp89) H-2Ld YPHFMPTNL (76, 113) HZI, Germany 
MCMV M139 H-2kb TVYGFCLL (74, 114) HZI, Germany 
MCMV M38 H-2kb SSPPMFRV (74) HZI, Germany 
VSV H-2kb RGYVYQGL (115) HZI, Germany 
 
3.1.6 Consumables & machines 
Name  Supplier 
1.4ml U bottom FACS tubes Micronic, The Netherlands 
1.5ml tubes SARSTEDT, Germany 
100µm Cell strainers BD Falcon, USA 
2ml tubes SARSTEDT, Germany 
50ml Falcon tubes Cellstar Tubes, USA 
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Accuri cytometer Accuri cytometers Inc. USA 
Flat-bottom 96 well plates Thermoscientific, Germany 
Haemocytometer  BRAND, Germany 
LSRII cytometer BD, USA 
Sonicator (Sonorex TK30) Bandelin, Germany 
Top table centrifuge Thermoscientific, Germany 
U-bottom 96 well plates BRANDplates, Germany 
 
3.1.7 Mice 
Male DBA/2xC57BL/6 (D2B6) F1 mice were purchased from Janvier (Le Genest, 
France), 129S2/SvPasCrlxBALB/cAnNCrl F1 (129B) mice were purchased from Charles 
River (Sulzfeld, Germany). Mice were housed in specific pathogen free (SPF) conditions 
at the HZI animal facility. Animal experiments were done according to animal welfare 
guidelines by FELASA and GV-SOLAS and were approved by the Lower Saxony State 
Office of Consumer Protection and Food safety (permit number 33.9-42502-04-
11/0426).  
 3.1.8 Viruses 
In all the experiments we used a BAC derived molecular clone of the mouse 
cytomegalovirus (116) as our wild type virus (MCMV). The virus stock was made on M2-
10B4 cells. The MHV-68 was kindly provided by Dr. H. Adler (117), Helmholtz Zentrum 
München, and the virus stock was produced on NIH3T3 cells. HSV-1 strain 17, VACV 
and recombinant VACV expressing an immunodominant peptide from HSV-1 (rVACV) 
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were obtained from Dr. J. Nikolich-Zugich (58, 118-120), University of Arizona, Tucson 
and grown on Vero cells. The Influenza virus PR8M which is closely related to the 
Mount Sinai strain of A/PR/8/34 (H1N1) referred to as “low pathogenic” virus was 
obtained from Dr. K. Schughart (121), HZI and was propagated in the chorio-allantoic 
cavity of ten days old embryonated chicken eggs for 48h at 370C. The vesicular 
stomatitis virus (VSV) Indiana strain, grown on BHK 21 cells, was given by Dr. Andrea 
Kröger (122), HZI.  
3.2 Methods 
3.2.1 Infection 
a. Infection of the D2B6 mice  
Six or two months old D2B6 mice were infected with herpesviruses, allowed to age till 
15 or 17 months of age respectively and then challenged with VSV. Mice were divided 
into three independent cohorts each with six groups of mice i.e MCMV, MHV-68, HSV-
1, VACV/rVACV, mock and the group which received a combination of the three 
herpesviruses at an interval of two weeks between infections (triple infection group). All 
the groups were infected intraperitoneally (i.p.) with a total volume of 200µl of the 
following doses of the viruses; MCMV 2x105pfu, MHV-68 1x106pfu, HSV-1 1x106pfu, 
VACV 1x106pfu. Nine and 15 months post priming with the herpesviruses, VACV or 
PBS, all the mice were challenged with 1x107 pfu of VSV by intranasal (i.n.) application 
of 20μl of virus suspension after the mice were fully anesthetized by i.p. injection of a 
cocktail of ketamine/xylazine.  
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b. Infection of the 129B mice 
129B mice were infected at the age of 6, 12 or 18 months with herpesviruses. At each 
time point two cohorts of mice (males and females) were infected either intraperitoneally 
with MCMV (2x105pfu), MHV-68 (106pfu), rVACV (106pfu), mock infected (200µl of PBS) 
or intranasally with Flu (2x104ffu). One group of mice received a combination of the two 
herpesviruses (MHV-68 and MCMV) at two weeks space between the first infection 
(MHV-68) and the next (MCMV). There was no HSV-1 group, because this mouse strain 
is highly sensitive to this virus.  All the mice were challenged with 107 pfu VSV i.n. 
approximately at the same age (17-18 months).  
3.2.2 Organs and peripheral blood collection/processing  
Two blood specimens were acquired from the retrobulbar venous plexus of each mouse 
anesthetized by isofluran. The blood was diluted in 300µl of heparin in HBSS (2U/ml). 
The first specimen consisted of exactly 100l and was used to determine absolute blood 
cell counts in an Accuri cytometer, while the second one had a volume of approximately 
140l and was used for in vitro stimulation assays.  Erythrocytes were removed from 
blood by osmotic shock lysis of cell pellets in 9ml of water, followed immediately by the 
addition of 3ml of 4xPBS, upon which the cells were centrifuged and the pellet was 
transferred into a U- bottom 96 well plates for staining or in vitro stimulation. Mice were 
euthanized by CO2 asphyxia and lymph nodes (mediastinal and inguinal) and spleen 
were harvested into 2ml tubes containing 1ml of RPMI. Spleen and lymph nodes were 
homogenized on 100µm-pore-size cell strainers, in 5ml of RPMI and erythrocytes were 
removed from spleen samples by ACK buffer lysis for 5 minutes. Spleenocytes were re-
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suspended in 1ml RPMI, counted using a haemocytometer (Neubauer chamber) and a 
volume equivalent to approximately 500K cells was taken for in vitro stimulation and 
flow cytometric analysis. Lymph node homogenates were centrifuged and the pellet was 
re-suspended in 200l of FACS buffer, 50l was transferred into 96 wells plate for the 
cell counting in an Accuri cytometer, while the rest was used for the in vitro stimulation 
assay. 
3.2.3 Preparation of the VSV lysate for the stimulation of CD4 T cells  
VSV lysate was made by infecting BHK21 cells at 100% confluency with the VSV at 
MOI of 0.01 for 24 hours, resulting in throughout infection. The infected cells were 
harvested into 50ml Falcon tubes, centrifuged at 1000rpm, washed once with 2ml of 
PBS, and re-suspended in 3ml of PBS followed by three freeze-thaw cycles and 
sonication for 60 seconds to release viral proteins from the cells. This was followed by 
another centrifugation step (1200rpm for 5 minutes) and the supernatant containing viral 
proteins was harvested, aliquoted and stored at -200C until the stimulation assay. The 
mock lysate (uninfected BHK21 cells) was treated in parallel with the VSV lysate and 
used in control assays, to identify unspecific responses directed against BHK-21 
proteins.  
3.2.4 In vitro neutralization assay (IgM and IgG concentration) 
Serum from the mice collected at day 7 or day 14 post VSV challenge was diluted 40-
folds in minimal essential medium containing 5% of heat-inactivated fetal calf serum, 
which was followed by serial 1:2 dilutions in the same medium. The diluted serum was 
mixed with equal volumes of medium containing 500 pfu of VSV, incubated at 370C, 5% 
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CO2 for 90 minutes, and transferred onto monolayers of Vero cells in 96-wells plates. 
Upon 60 minutes incubation at 370C, 5% CO2, the monolayers were overlaid with 
DMEM containing 1% methylcellulose and incubated at 370C, 5% CO2. 48h later, the 
overlay was removed and cells were fixed and stained in 0.5% crystal violet dissolved in 
5% formaldehyde, 50% ethanol and 4.25% NaCl. After the plates dried, the serum 
dilution that reduced the number of plaques by 50% was taken as the titer. To 
determine the IgG titer, the serum was pre-treated with an equal volume of 280 mM 2-
Mercaptoethanol for one hour at room temperature prior to dilution and sample 
processing as described above  
3.2.5 Peptide and lysate stimulation of CD8 and CD4 T cells  
All the peptides used in this study were synthesized at the HZI peptide facility and 
HPLC purified to reach 65-95% purity (for a list of peptide sequences see section 3.1.5). 
Lymphocytes were re-stimulated at 370C with peptides listed in section 3.1.5 diluted in 
RPMI-supplemented medium (5% fetal bovine serum, 1% Glutamine, 1% 
Penicillin/streptomycin) at a concentration of 1µg/ml for one hour followed by five 
additional hours of stimulation in the presence of 10µg/ml Brefeldin A (BFA). Co-
stimulatory antibodies CD49d and CD28 were added in the RPMI/peptide mixture.  For 
MCMV and the triple infection group, an L(d) restricted peptide derived from the IE1 
protein was used and for the HSV-1 group, we used the K (b)-restricted peptide from 
the glycoprotein B of HSV-1 (HSV-1 gB) (see section 3.1.5). Samples from the mice 
after the VSV challenge were restimulated with a peptide derived from the VSV 
nucleocapsid protein N52-59 (123). Medium containing only the co-stimulatory 
antibodies (CD28 and CD49d) was used as a negative control for the stimulation. For 
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CD4 T cells stimulation, the VSV lysate or mock infected BHK21 cell lysate diluted in 
RPMI-supplemented medium and in the presence of the co-stimulatory antibodies was 
used to re-stimulate the cells for one hour followed by another eight hours stimulation in 
the presence of Brefeldin A. Stimulation of the lymphocytes was performed in U-bottom 
96-well plates in a total volume of 100µl. 
3.2.6 Immunofluorescence staining and flow cytometric analysis 
Surface phenotypic markers on cells were stained prior to cell fixation and intracellular 
cytokine staining. Surface staining was performed with anti- CD62L-eFluor 605NC, 
αCD8-PerCp-Cy5.5, CD11a-PE-Cy7, KLRG1-Biotin, CD4-Pacific blue, CD44-Alexa 
Fluor 700, CD3-APC-eFluor 780, CD127-PE, Nkp46-PE, NKG2A/C/E-FITC and for 
intracellular staining the following antibodies were used: IFNγ-APC and TNFα-FITC. 
Biotinylated antibodies were detected by secondary staining with streptavidin-Brilliant 
Violet 570. Briefly, cells were incubated with the antibodies against the surface markers 
in a total volume of 50µl for 30 minutes at 4oC in darkness followed by two washing 
steps with 200µl of FACS buffer. When biotinylated antibodies were used in the panel, 
an additional 15 minutes incubation step with streptavidin-brilliant Violet 570 was done, 
followed by two washing steps as above. Samples were suspended into 100µl of FACS 
buffer prior to acquisition in an LSRII apparatus or intracellular staining. 
Intracellular cytokine staining was done as follows: samples were fixed in 100µl of 
fixation buffer for 5 minutes, followed by addition of 100µl of permeabilization buffer and 
incubation for 3 minutes. Cells were washed in permeabilization buffer and incubated 
with the intracellular antibodies diluted in permeabilization buffer for 30 minutes followed 
by two washing steps before the acquisition using the LSRII machine. 
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Samples for the absolute cell count were first incubated with the VSV-Dextramer-PE for 
15 minutes in the darkness at room temperature which was followed by a 20-minute 
staining with the surface antibodies: CD4-APC, CD8-PerCP-Cy5.5, CD62L-FITC or 
CD44-FITC. Samples were washed twice with FACS buffer and then acquired.  
Intracellular (nuclear) staining for regulatory T cells (Tregs) was done with the mouse 
regulatory T cell staining kit from the eBioscience company. Briefly, cells were surface 
stained for 30 minutes at 4oC in the darkness with CD8-PerCp-Cy5.5, CD4-FITC, CD25-
APC in a total volume of 50µl. Cells were then washed twice with 200µl of FACS buffer 
and incubated with 100µl of Fixation/Permeabilization buffer for 30 minutes in the 
darkness, which was followed by two washing steps with the permeabilization buffer. 
The cells were incubated with the Foxp3-PE antibody (clone FJK-16s; eBioscience) or 
with the isotype control in permeabilization buffer for 30 minutes at 4oC in the darkness. 
Cells were then washed twice with the same buffer, suspended in 100µl FACS buffer 
and acquired in the Accuri cytometer. 
3.2.7 Data analysis 
FACSDiva software was used for acquisition of flow cytometry samples (BD, San Jose, 
USA), whereas Flowjo software (Treestar, Ashland, USA) was used for the analysis. 
Samples acquired by the Accuri cytometer were analyzed with CFlow software, version 
1.0.227.4 (Accuri cytometers,Inc., Michigan, USA). Statistical analysis was done using 
Graphpad prism, version 5.04 (GraphPad software, Inc., California, USA). 
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Chapter 4 
4.0 Results 
4.1 HOMEOSTATIC CHANGES IN THE ADAPTIVE IMMUNE SYSTEM OF MICE 
INFECTED WITH HERPESVIRUSES 
4.1.1 Infection with herpesviruses causes permanent changes in the CD8 
compartment of mice  
Three cohorts of D2B6 (F1) mice were infected with various herpesviruses, vaccinia 
(VACV) or mock infected at the age of 6 months and the phenotype of lymphocytes was 
monitored for a period of nine months (Figure 4.1).  VACV was used as a paradigmatic 
non-persistent virus, to exclude that phenomena observed in herpesvirus infection were 
common to any infection. The fraction of CD8 effector memory (EM) cells in mice 
infected with HSV-1, MCMV, MHV-68 or a combination of the three herpesviruses was 
compared to the fraction of the same cells in mice infected with VACV, or to cells from 
the mock group (Figure 4.2). All infections resulted in an initial expansion of the CD8 
EM cells, upon which the response contracted in VACV or HSV-1 infected mice to levels 
from the mock-infected group, while mice infected with MCMV, MHV-68 or a 
combination of the three herpesviruses showed almost no contraction of the EM pool, 
because its fraction was maintained at ~50-60%. Interestingly, the EM contraction in 
HSV-1 infection was transient, because by 13 weeks post infection their number started 
to gradually rise again and reached the same level as in mice infected with other 
herpesviruses (Figure 4.2B). The triple infection had small, but consistent, additive 
effects over the groups infected with a single Herpesvirus.  
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The response kinetic to the IE1 (pp89)-derived peptide YPHFMPTNL, which is an MHC-
I restricted peptide associated with memory inflation in mice with H-2Ld haplotype was 
compared between mice carrying MCMV or a combination of the three herpesviruses. 
Mock infected mice were used as negative control (Figure 4.2C).  MCMV-only infection 
induced a kinetic characterized by an expansion of the fraction of responding CD8 T 
cells from 2% until it reached 3.4% at week 21.7 and then stabilized, which was 
somewhat lower than the results previously observed in Balbc mice (75, 79). This 
discrepancy might be explained by the strains of mice used, as here  D2B6 F1 mice 
were used (a cross of H-2Kd and H-2Kb haplotype) which increase the ability of cells 
from these mice to present peptides to the T cells and this might have led to peptide 
competition (124). Interestingly, response kinetic to IE1 in the triple infection group was 
characterized by an initial response peak at one week post infection followed by a sharp 
contraction until week four, upon which the fraction of peptide specific cells stabilized at 
approximately 1.4%.  
Results 
36 
 
 
Figure 4.1: Experimental set up and gating strategies. (A) Three cohorts, each with 
six groups of D2B6 F1 mice were infected with the indicated virus (es) or mock infected 
(PBS) at the age of six months. Each group had at least 15 mice. The mice were bled at 
indicated time points to monitor changes in the phenotypes of T or B cells until nine 
months post infection (15 months of age), when all the groups were challenged with 
VSV. At day 7 and 14 post challenge, the T cells and antibody response to the VSV 
challenge were analyzed. (B) Progressive gating strategies used to identify the 
population of T and B cells are shown.  
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Figure 4.2: Herpesvirus infection results in permanent homeostatic changes in 
the CD8 Compartment. (A) Blood was collected before and after infection and CD8 T 
cell subsets were analyzed by multicolor flow cytometry to define the expression of 
CD62L and CD44 surface markers (upper panels) and intracellular IFNγ levels upon 
MCMV IE1 (pp89) peptide in vitro restimulation (lower panels). (B) Time kinetic of the 
fraction of CD8 EM from infection until nine months later, (C) Peripheral blood 
leukocytes from the MCMV, mock or triple infected group were collected over a period 
of nine months. Lymphocytes were stimulated in vitro with the MCMV IE1 (pp89) 
peptide and the kinetic of CD8 T cells responses, assessed by IFNγ intracellular 
staining is shown.  
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a similar trend towards lower fractions of these cells in the triple infection group (Figure 
4.3A). On the other hand, the fraction of CD8 T cells responding to the HSV-1 
immunodominant peptide from single infection with HSV-1 was comparable to the triple 
infection group (Figure 4.3B), arguing that the weaker response to MCMV peptides was 
a phenomenon associated with MCMV infection only. The discrepancy between the 
MCMV-infection and the triple-infection group in the frequency of CD8 T cells specific 
for the MCMV inflationary peptides might be due to a competition for antigen-specific 
CD8 cells in multiple infections, in line with the observation that the total EM pool was 
only mildly increased. Alternatively, since infection of the mice was done in an order that 
mice were first infected by HSV-1 then MHV-68 and lastly MCMV at two weeks gap 
between one infection to the next, MHC-I down regulation as a viral immune evasion 
strategy of the HSV-1 and/or MHV-68 might have played a role. Further studies are 
needed to ascertain the validity of these hypotheses. 
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Figure 4.3: MCMV and not HSV-1 response to the inflationary peptides is reduced 
in mice carrying multiple herpesviruses. (A) D2B6 mice infected with 2x105 pfu 
MCMV, a combination of the three herpesviruses (106pfu HSV-1, 106pfu MHV-68 and 
2x105pfu MCMV) or mock-infected at the age of two months were bled after 14 months. 
The blood leukocytes were split into three parts and in vitro stimulated with three MCMV 
inflationary peptides, followed by intracellular staining for IFNγ response. (B) D2B6 mice 
infected as above were bled and the leukocytes were stimulated with the HSV-1 gB 
peptide and stained for IFNγ. Each dot represents a mouse and the horizontal line 
represents median of the group.  
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senescence (59, 125). CD94/NKG2 heterodimers interacts with non-classical MHCI 
molecules (HLA-E in humans and Qa-1b in mice). The three isoforms of NKG2 which 
are well studied are NKG2A, NKG2C and NKG2E where NKG2A provides an inhibitory 
signal and the other two an activation signal. Studies have shown that, NKG2A up-
regulation on CD8 T cells during virus infection and the interaction with the Qa-1b 
molecules on the APCs inhibits MHC I restricted cytotoxicity (126, 127).  Moreover, 
expression of KLRG1 and NKG2A on CD8 T cells from MHV-68 infected mice has been 
shown to confer more protection to a challenge with the same virus (128). Several 
studies on CD8 T cells expressing NKG2A use a monoclonal antibody which detects all 
the three NKG2 isoforms (NKG2A/C/E) with the reason that NKG2A is the dominant 
transcript expressed by nearly all antigen-specific CD8 T cells and on the other hand 
the expression of NKG2A and NKG2C are mutually exclusive (129-131).  In this study,  
the phenotypes of NK and CD8 T cells were analyzed (Figure 4.4), to determine 
whether there is a difference in the fraction of CD8 T cells expressing KLRG1 or 
NKG2A/C/E in herpesvirus-infected and the mock group. Their fractions were compared 
nine months post infection (Figure 4.5 upper panel), and to control if changes were 
specific for the CD8 fraction, or a reflection of general upregulation of KLRG1 and 
NKG2A, their expression on NK cells were also compared (Figure 4.5 lower panel). The 
fraction of CD8 T cells expressing KLRG1 was significantly higher in the MCMV infected 
and in the triple-infected group than in the mock-infected controls. HSV-1 and MHV-68 
infection showed a trend towards increased responses, but it did not reach statistical 
significance (Figure 4.5 upper panel). The same results were observed in the fraction of 
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CD8 T cells expressing NKG2/A/C/E (Figure 4.6 upper panel). On the other hand, there 
were no significant differences in the fraction of NK cells (Figure 4.6 lower panel). 
 
 
Figure 4.4: Progressive gating strategies used to identify the population of T and 
NK cells. Nine months post infection, PBMCs from the D2B6 mice were surface stained 
to compare changes in the phenotypes of the CD8 T cells and NK cells. Cells gated as 
NKp46+CD3- or CD4-CD8+ were analyzed in details on panels in figures 4.5 and 4.6.  
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Figure 4.5: Infection with MCMV significantly expands the fraction of CD8 EM cells 
expressing KLRG1. Nine months post infection, the fraction of CD62L-KLRG1+ CD8 T 
cells (top panel) and KLRG1+ NK cells (bottom panel) in infected mice was compared to 
the mock infected control group. Each dot represents a mouse, the line represents the 
median and the red dots shows groups which had p < 0.05 (Kruskal-Wallis test followed 
by Dunns post-analysis).  
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Figure 4.6: Infection with MCMV significantly expands the fraction of CD8 EM cells 
expressing NKG2A/C/E. Nine months post infection, the fraction of CD62L-
NKG2A/C/E+ CD8 T cells (top panel) and NKG2A/C/E+ NK cells (bottom panel) in 
infected mice was compared to the mock infected control group. Each dot represents a 
mouse, the line represents the median and the red dots shows groups which had 
p<0.05 (Kruskal-Wallis test followed by Dunns post-analysis).  
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triple-infected group showed a statistically significant increase in the fraction of CD4 EM 
cells, whereas mice infected with single herpesviruses showed a similar trend but did 
not reach the level of statistical significance. The VACV group showed no obvious 
difference in the frequency of these cells.  
 
Figure 4.7: Multiple herpesvirus infection expands the fraction of CD4 T cells with 
EM phenotype. Eight months post infection of D2B6 mice, the CD4 T cells from the 
peripheral blood were analyzed for the expression of CD44 and CD62L. The frequency 
of CD62L-CD44+ cells was compared by Kruskal-Wallis test followed by Dunns post 
analysis. Each dot represents a mouse and the line is the median of the group. The 
group with p < 0.05 is indicated by red dots.   
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and thus suppress the immune response of effector T-cells. In vitro studies with human 
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specific EM CD8 T cells have been also shown in IL10 knock-out mice infected with 
MCMV, and since these mice had lower copy numbers of latent MCMV genomes than 
the wild type mice, this argues for  enhanced control of viral replication by pro-
inflammatory cytokines (133). To determine if latent herpesvirus infection altered the 
frequency and the absolute number of the Tregs, the fraction and the absolute number 
of CD4 T cells expressing the transcription factor Foxp3 and the surface receptor CD25 
were analyzed at one-year post infection (Figure 4.8A). Only the MHV-68 group showed 
a significantly reduced frequency of Tregs as compared to the mock-infected group, 
whereas other herpesviruses showed a similar trend, but no statistically significant 
difference (Figure 4.8B upper panel). On the other hand, the absolute number of Tregs 
in the mice infected with the herpesviruses was not significantly different in any group 
(Figure 4.8B lower panel). Interestingly, infection with vaccinia virus resulted in relative 
and absolute Treg counts that were slightly increased, but not to a point of statistical 
significance. 
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Figure 4.8: The fraction of Tregs but not the absolute count is reduced in the 
MHV-68 infected mice. (A) Cells from the CD4+ gate were analyzed on the expression 
of CD25 and Foxp3 (upper plot). The lower dot plot show cells stained with the isotype-
control antibody for FoxP3 (rat IgG2a), to exclude unspecific antibody binding. (B) D2B6 
mice infected with the indicated viruses were bled at one year post infection and 
PBMCs were stained for Tregs markers (CD4+, Foxp3+ and CD25+). The upper panel 
shows the percentage of Tregs in the CD4 pool and the lower panel shows their 
absolute count per ml of blood. Each dot represents a mouse and the horizontal line 
represents median of the group. The group with red dots had p<0.05 (Kruskal-Wallis 
test followed by Dunns post analysis   
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4.1.5 Herpesviruses do not affect the peripheral memory B cells compartment 
There are two kinds of memory B cells which are distinguished by the expression of IgM 
(134-136) ; conventional memory B cells which do not express IgM but IgG and IgM 
memory B cells which express IgM but not IgG. The latter is said to persist longer after 
the clearance of an infection whereas IgG+ memory cells are described as the frontline 
responders to infections (137). Eight months post infection, the blood lymphocytes were 
stained for memory B cell markers.  The fraction of both “conventional” memory B cells 
and IgM memory B cells were analyzed on expression of CD3- CD19+ CD80+IgM- and 
CD3-CD19+CD80+IgM+ respectively (Figure 4.9). The fraction of memory B cells was 
comparable in all the infection groups and for both types of memory subset, suggesting 
that long-term herpesvirus infection does not affect this subset of lymphocytes.  
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Figure 4.9: Herpesviruses do not affect the frequency of memory B cells. Eight 
months post priming D2B6 mice were bled and the lymphocytes were stained and 
analyzed on the expression of CD19+, IgM+/- and CD80+ to define the memory B cell 
subsets. Each dot represents a mouse and the line is a median of the group.  Kruskal-
Wallis test followed by Dunns post analysis test was used  
 
4.2 EFFECTS OF HERPESVIRUSES ON THE RESPONSE TO A NEW INFECTION 
To determine whether the immune response to new infections is affected in mice 
carrying herpesviruses, mice were challenged with VSV, a neurotropic virus related to 
the rabies virus, whose control requires Ig class switch.  Weight loss was monitored, 
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specific immunoglobulin (Ig) titer in herpesviruses infected mice was compared with that 
from mock-infected mice.  
 Weight loss and survival  was monitored in the group of mice infected with the primary 
viruses at the age of 6 months and challenged with VSV after 9 months (Figure 4.10A, 
C)  or mice infected at 2 months of age and challenged 15 months later (Figure 4.10B, 
D). In the first experiment, VSV challenge at nine months after the infection with 
herpesviruses resulted in no significant difference in weight loss between any 
herpesvirus-infected group and the mock control (Figure 4.10A). The triple infection 
group showed more weight loss as compared to the weight loss in the MCMV-infected 
group which proceeded exactly like in the mock control (Figure 4.10A). On the other 
hand, MHV-68 infected mice recovered earlier, while the recovery was delayed in mice 
infected with HSV-1 alone or mice infected with VACV. The mortality showed no 
significant trends, with one mouse dying on day 2, 5 and 12 in the VACV, HSV-1 and 
mock group respectively (Figure 4.10C). 
In the second experiment, where challenge occurred 15 months post primary infection, 
the MCMV and the mock had similar kinetic of weight loss, reflecting the previous 
experiment, but surprisingly the HSV-1 group showed the lowest weight loss (Figure 
4.10B). Similarly, in this experiment the triple infected mice showed a more moderate 
weight-loss than mock-infected controls. MCMV had the lowest survival rate (60%) 
followed by the MHV-68 group (80%) (Figure 4.10D). The discrepancies between the 
two experiments might be explained either due to the difference in the age of the mice 
at primary infection, the length of latent infection, or this might reflect a stochastic 
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phenomenon that was not associated with the latent viruses the mice were previously 
infected with.   
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Figure 4.10: Kinetics of weight loss and survival curve of the D2B6 mice. (A, C) 
Three cohorts of D2B6 mice at the age of 15 months (9 months post primary infection) 
were all challenged with VSV and then weight loss was monitored until day 13 and 
survival until day 14. (B, D) Two cohorts of D2B6 mice at the age of 17 months (15 
months post primary infection) were all challenged with VSV and then weight loss was 
monitored until day 13 and survival until day 14  
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In order to understand the implication of the phenotypic changes  observed in this study,  
mice were sacrificed  at day 7 or day 14 after the challenge and compared the adaptive 
immune response to the VSV from the peripheral blood, spleen or lymph nodes of mice 
infected with herpesviruses to the control mice infected with non-persistent virus or 
mock-infected (Figure 4.11). 
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Figure 4.11: A Flow chart diagram to summarize different steps during sample 
processing 
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4.2.1 Effects of Herpesvirus infection on CD8 T cell response to VSV 
We published recently that the CD8 response to West-Nile virus challenge is diminished 
in MCMV infected mice, and hence we reasoned that the same may occur in VSV 
infection. To test this hypothesis,  the fraction of CD8 T cells responding by cytokine 
release to the H-2Kb VSV peptide (RGYVYQGL) was compared after in vitro 
restimulation (Figure 4.12A).  Mice were challenged with VSV at the age of 15 months 
(9 months post primary infection) and assessed the frequency of blood CD8 T cells 
responding to the VSV at seven days post challenge. Mice carrying latent MCMV or all 
three herpesviruses showed a significant decrease of CD8 T cells responding to a 6h in 
vitro restimulation  with an immunodominant VSV peptide  (Figure 4.12B), consistent 
with our published data (79). Therefore, our data showed that fraction of antigen-
responding CD8 T cells in mice latently infected with MCMV, alone or in combination 
with other viruses (the triple-infected group), are diminished. Two weeks post challenge, 
CD8 T cell responses contracted in the spleen and blood of all the groups, and there 
were no significant differences between groups. Interestingly, at 14 days post infection, 
the fraction of VSV-responding cells was significantly higher in the draining lymph node 
of the triple-infected group, but not in the single-infection with any herpesvirus. Hence 
these data indicate that contraction of the CD8 T cell responses may be delayed in the 
draining lymph nodes of mice infected with a combination of the three herpes viruses.    
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Figure 4.12: Less frequency of responding CD8 T cells to VSV peptide from MCMV 
infected mice at day seven post challenge. Cells were isolated as shown in figure 
4.11 and stimulated with the VSV immonodominant peptide (RGYVYQGL) for 1 hour 
followed by 5 hours in the presence of Brefeldin A. (A) A representative dot plots 
showing the percentage of CD8 T cells responding to the peptide stimulation by IFNγ 
production (upper panel) and negative controls, incubated in the same conditions, but 
without the peptide (lower panel). (B) CD8 T cell response to VSV from the peripheral 
blood at day 7 and 14 post challenge was analyzed (upper panel). The lower panels 
show responses at day 14 from the lymphoid organs (spleen and mediastinal LN) of the 
same mice. Each dot represent a mouse, the line represent median and the red dots 
represent groups which had p-value <0.05 when compared to the mock control by using 
Kruskal-Wallis test followed by Dunns post analysis.  
 
To test if these results may be observed independently of the length of the latent virus 
infection, analysis of the CD8 response to VSV challenge in D2B6 mice infected at the 
age of two months, and challenged with VSV after 15 months (at the age of 17 months) 
was done. Moreover, the analysis was not only in the fraction of VSV-responding CD8 T 
cells, but also their absolute numbers, as well as the total CD8 count in PBMC 
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populations and in lymphoid organs. The frequency of VSV specific CD8 T cells in the 
blood was lower in mice infected with MCMV or all three viruses at 7 and at 14 days 
post challenge (Figure 4.13 upper panels), although not to a level where the difference 
would be significant. Interestingly, the absolute number of these cells was essentially 
identical in all the groups (Figure 4.13 middle panels), despite the differences in the 
relative counts. The difference between the relative and absolute count of VSV-specific 
cells could probably be explained by higher total counts of CD8 T cells in herpesvirus-
infected mice, which trended up in all groups and was significantly higher in the triple-
infected group at day 7 post challenge. (Figure 4.13 lower panel).  
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Figure 4.13: Number of VSV dextramer positive and the total peripheral CD8 T cell 
at day 7 and 14 post challenge. D2B6 mice infected with MCMV, a combination of the 
three herpesviruses, rVACV or mock-infected at the age of 2 months were challenged 
with VSV after 15 months. The frequency (upper panel), absolute number (middle 
panel) of VSV specific CD8 T cells and total CD8 T cells (lower panel) were compared 
to the mock group. Each dot represent a mouse, the line represents median of the 
group and the red dots represent groups which showed a statistically significant 
difference (p<0.05, Kruskal-Wallis test followed by Dunns post analysis)    
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identical in mice infected with herpesviruses and in the control groups (Figure 4.14 top 
panels)., while the absolute count of VSV-specific and total CD8 cells was slightly 
elevated (Figure 4.14 middle and bottom panels). 
 
 
Figure 4.14: Numbers of VSV dextramer positive and the total CD8 T cell at day 14 
post challenge from the lymphoid organs. D2B6 mice infected with MCMV, a 
combination of the three herpesviruses, rVACV or mock-infected at the age of 2 months 
were challenged with VSV after 15 months. The frequency (upper panel), absolute 
number (middle panel) of VSV specific CD8 T cells and total CD8 T cells (lower panel) 
were compared to the mock group. Each dot represent a mouse, the line represents 
median of the group (Kruskal-Wallis test followed by Dunns post analysis)    
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Therefore, in mice infected for a longer period of time there was similar reductions in the 
fractions of responder cells, but the extension of our analysis to include absolute counts 
of responding cells revealed, unexpectedly, that the responses were not decreased in 
absolute terms in the peripheral blood or in other organs.  
4.2.2 The time from primary infection with herpesviruses to the challenge is not 
crucial for the homeostatic or functional changes occuring neither in the T nor 
the B cell compartment 
To validate if the results obtained with the D2B6 (F1) mice were generally applicable to 
other mouse strains or specific for this mouse strain, similar experiments in 
129S2/SvPasCrl x BALB/cAnNCrl F1 mice (129B) were performed. Moreover, to test if 
the length of time from herpesvirus infection till the encounter with a new unrelated 
infection affects the strength of the immune response,  mice from the same litter were 
primed with herpesviruses early or later in their life, and challenged with VSV at the age 
of 18 months (Figure 4.15).  
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Figure 4.15: In vivo experimental plan.  129B mice were infected intraperitoneally at 
3, 9, 15 or 18 months of age with individual herpesviruses (i.e. MCMV and MHV-68), or 
their combination. Controls were infected with rVACV, influenza (flu) virus, or mock 
infected. Each experimental group consisted of at least five mice and all experiments 
were independently repeated to confirm results.  At the age of 18 months, all the mice 
were intranasally challenged with VSV and 7 days post challenge blood and lymph 
nodes were analyzed for immune response to VSV.   
 
The blood fraction of VSV specific CD8 T cells was compared in mice challenged with 
VSV at 7 days, 3 months or 9 months post infection with herpesviruses. To evaluate the 
fraction of antigen-specific cells in total and the fraction that was functionally active, half 
of the blood samples were stained with peptide-MHC multimers, whereas the other half 
was subject to a functional assay by peptide in vitro restimulation and intracellular IFNγ 
staining, using the same peptide as the one used in the multimer. Consistent with our 
previous results, the mice infected with MCMV showed significantly lower frequencies of 
antigen specific cells (Figure 4.16 upper panels), and this could be observed at all times 
tested. Similarly, mice infected with MHV-68 and MCMV in combination showed lower 
fractions of dextramer positive cells at three or nine months post primary infection (this 
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condition was not tested in mice infected for one week). Functional assays showed 
similar trends: The CD8 T cell response to stimulation with the VSV peptide was 
significantly lower in VSV challenged mice at one week post MCMV infection, while the 
median responses were lower, but not significantly, in the cohorts of mice challenged at 
three or nine months post MCMV infection (Figure 4.16 middle panels). On the other 
hand, the fraction of CD8 T cells with the EM phenotype was significantly higher in the 
MCMV and in the double-infected group, and this was significant in mice challenged at 
7 days or three months post primary infection, while a similar, but non-significant trend 
was observed at nine months post infection, Interestingly, rVACV infection resulted in a 
significantly higher fraction of the EM CD8 T cells compared to the mock group at 7 
days post infection, although this was not the case in mice infected with influenza 
(Figure 4.16 lower panels). 
Results 
62 
 
 
Figure 4.16: CMV infection results in low frequency of CD8 T cells responding to 
VSV, but elevated frequency of CD8 EM, regardless of the time of challenge. 129B 
Mice infected with MCMV, MHV-68, combination of MCMV and MHV-68 (Double), 
rVACV, Flu or mock infected at the age of 9, 15 and 18 months were all challenged with 
VSV at the age of 18 months. Seven days post challenge; the fraction of CD8 T cells 
specific for the VSV dextramer (upper panels), CD8 T cells responding to the VSV 
peptide (middle panels) and the fraction of the CD8 EM (bottom panels) were compared 
to the mock group. Each dot represents a mouse and the red dots represent groups 
which showed a statistically significant difference (p<0.05, Kruskal-Wallis test followed 
by Dunns post analysis)   
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4.2.3 Herpesvirus infection does not affect the absolute number of CD8 T cells 
responding to VSV challenge 
While the percentage of VSV responding cells was consistently lower in mice infected 
with MCMV, it was not clear if this would be matched by a similar decrease of the 
response in absolute terms. Therefore, the absolute responses to VSV peptides were 
evaluated in the same cohorts shown in the previous figure. Interestingly, the absolute 
number of VSV specific CD8 T cells measured by dextramer staining or in vitro VSV 
peptide stimulation from mice infected with the herpesviruses was comparable to the 
mock group regardless of the time at which the primary infection was done (Figure 4.17 
upper and middle panels). The total number of blood CD8 T cells in the same mice was 
significantly higher in the groups of mice infected with MCMV compared to the mock 
group, while the MHV-68 group and the double infection group had significantly higher 
numbers in the cohort of mice challenged three months post infection (Figure 4.17 lower 
panels). Therefore, the decrease in the percentage of CD8 cells that are specific for the 
VSV antigen (Figure 4.16) was not caused by the decrease of their count, but rather by 
the increase of the size of the CD8 pool (Figure 4.17), and mainly by the huge increase 
of the EM subset of CD8 cells (Figure 4.16, lower panels).  
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Figure 4.17: Latent infection with herpesviruses does not affect the absolute 
count of the VSV specific CD8 T cells. 129B Mice infected with MCMV, MHV-68, 
combination of MCMV and MHV-8 (double), rVACV, Flu or mock infected at the age of 
9, 15 and 18 months were all challenged with VSV at the age of 18 months. Seven days 
post challenge; the absolute number of VSV dextramer positive CD8 T cells (upper 
panel), CD8 T cells responding to the VSV peptide (middle panel) and the total CD8 T 
cells (lower panels) were compared to the mock group. Each dot represents a mouse 
and the red dots represent groups which showed a statistical significant difference 
(p<0.05, Kruskal-Wallis test followed by Dunns post analysis)  
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4.2.4 Herpesvirus infection does not impact the frequency of functionally active 
CD8 T cells within the pool of CD8 T cells that are specific for the VSV antigen  
Since the fractions of dextramer specific CD8 T cells were significantly smaller, but a 
less pronounced decrease of the cell populations that responded to the antigen by IFNγ, 
raised a possibility that herpesviruses might affect the fraction of CD8 T cells 
responding to the VSV peptide within the antigen-specific population. Therefore, the 
fraction of CD8 T cells which were functionally active (producing IFNγ after in vitro 
peptide stimulation) was analyzed within the pool of dextramer positive cells, since the 
same peptide used for the stimulation was a constituent of the MHC-peptide complexes 
on the dextramer molecule. The fraction of functional cells was similar in all 
experimental groups and controls (Figure 4.18). While in this study analysis of other 
properties of these cells (e.g. degranulation activity, cytotoxicity, or proliferative 
capacity) were not done, these data suggested that herpesviruses do not affect the 
functional cytokine responses to antigen stimulation of CD8 T cells generated against a 
new viral infection.  
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Figure 4.18: Latent herpesvirus infection does not affect the frequency of CD8 T 
cells responding to the in vitro peptide stimulation within the VSV specific cells. 
129B Mice infected with MCMV, MHV-68, combination of MCMV and MHV-68 (Double), 
rVACV, Flu or mock infected at the age of 9, 15 and 18 months were all challenged with 
VSV at the age of 18 months. Seven days post challenge; the fractions of CD8 T cells 
responding to the VSV peptide within the dextramer positive population were analyzed 
(Kruskal-Wallis test followed by Dunns post analysis). Each dot represents a mouse  
 
4.2.5 The increase in the absolute number of blood CD8 T cells in MCMV infected 
mice is a result of the increase in the number of EM cells in the peripheral blood 
but not in lymph nodes. 
The enlargement of the blood CD8 T cell pool in MCMV infected mice raised the 
question about the provenance of these cells. While it was likely that the relative 
increase of the EM subset in the peripheral blood (see Figure 4.16 lower panels) may 
have affected the size of the total CD8 pool, it remained unclear if this would be 
restricted to the blood pool, or a result of an increase of the EM subset in the sites 
where the adaptive immune response is initiated, namely in the draining lymph nodes. 
The absolute number of CD8 T cells with EM phenotypes (defined as CD127-CD44+) in 
the peripheral blood was significantly higher in the group of mice which were previously 
infected with MCMV and challenged with VSV either one week, three or nine months, 
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and similar results were observed in the double infected groups (Figure 4.19 upper 
panel). The absolute number of EM CD8 T cells in the mediastinal (draining) lymph 
node was essentially identical in all the tested conditions (Figure 4.19 middle panels). 
Likewise, the size of the EM pool was not changed in inguinal (non-draining) lymph 
nodes of any mouse group (Figure 4.19 lower panels). On the other hand, the EM pool 
was larger in draining than in non-draining lymph nodes (Figure 4.19 middle and lower 
panels), strongly arguing that VSV infection activated the CD8 cells specifically in the 
draining lymph node. Therefore, our results argue that the increases in the EM CD8 T 
cells in peripheral blood were unlikely a result of cells responding to the VSV challenge, 
but rather were a reflection of the CMV specific induction of EM cells (please see also 
Figure 4.2). 
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Figure 4.19: The increase in the absolute count of total peripheral CD8 T cells is a 
result of an increase in the absolute number of the EM subsets. 129B Mice infected 
with MCMV, MHV-68, a combination of both MCMV and MHV-8 (double), rVACV, Flu or 
mock infected at the age of 9, 15 and 18 months were all challenged with VSV at the 
age of 18 months. Seven days post challenge; the absolute number of CD8 T cells from 
the peripheral blood and lymph nodes with EM phenotype were compared to the mock 
group. Each dot represent a mouse and the red dots represent groups which showed a 
statistical significant difference (p<0.05, Kruskal-Wallis test followed by Dunns post 
analysis)  
  
While the EM pool was elevated in the blood of MCMV-infected mice, this did not 
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peripheral blood of MCMV or double-infected mice was significantly higher than in 
mock-infection controls (Figure 4.20 upper panels). Similar results were obtained in the 
group that was primed with MHV-68 and challenged with VSV three months later. In the 
MCMV group challenged with VSV a week post primary infection there was a similar 
trend, but it did not reach significance. On the other hand, there were no significant 
differences in the size of the CM pool in lymph nodes. (Figure 4.20 middle and lower 
panels). Finally, the absolute number of naïve (CD44-CD127+) CD8 T cells in the 
peripheral blood and lymph nodes of the same mice were assessed. 
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Figure 4.20: The increase in the absolute count of total peripheral CD8 T cells is 
as a result of an increase in the absolute number of the CM subsets. 129B Mice 
infected with MCMV, MHV-68, a combination of both MCMV and MHV-8 (double), 
rVACV, Flu or mock infected at the age of 9, 15 and 18 months were all challenged with 
VSV at the age of 18 months. Seven days post challenge; the absolute number of CD8 
T cells from the peripheral blood and lymph nodes with CM phenotype were compared 
to the mock group. Each dot represent a mouse and the red dots represent groups 
which showed a statistical significant difference (p<0.05, Kruskal-Wallis test followed by 
Dunns post analysis)  
 
 Interestingly, the numbers of naïve blood CD8 cells were higher in mice infected with 
MCMV, and this was significant in mice infected for 7 days or three months prior to 
challenge, (Figure 4.21 upper panels). There was no significant difference in the 
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absolute number of the naïve CD8 T cells in the draining or non-draining lymph nodes in 
any experimental group (Figure 4.21 middle and lower panels).  
 
 
Figure 4.21: The absolute number of peripheral naïve CD8 T cells is increased in 
MCMV infected mice. 129B Mice infected with MCMV, MHV-68, a combination of both 
MCMV and MHV-8 (double), rVACV, Flu or mock infected at the age of 9, 15 and 18 
months were all challenged with VSV at the age of 18 months. Seven days post 
challenge; the absolute number of CD8 T cells from the peripheral blood and lymph 
nodes with a naïve phenotype were compared to the mock group. Each dot represent a 
mouse and the red dots represent groups which showed a statistical significant 
difference (p<0.05, Kruskal-Wallis test followed by Dunns post analysis)  
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4.2.6 Persistent herpesvirus infection does not affect the total number of CD8 T 
cells and absolute number of VSV specific CD8 T cells in the draining and non-
draining lymph nodes 
Our results argued that MCMV infection does not alter the number of VSV specific cells 
in the peripheral blood, but that it masquerades as a decrease of the percentage of 
VSV-responding cells in the CD8 pool, because it increases the total number of CD8 
cells. It remained unclear if herpesvirus infections altered the relative or absolute 
response to VSV in other lymphatic organs. Therefore, the effects of herpesvirus 
infection on the number of total CD8 T cells and VSV specific cells in draining lymph 
nodes were tested. No infection condition altered the size of the CD8 pool or of the 
VSV-dextramer positive subset in the lymph nodes of mice challenged with VSV at nine 
months post primary infection (Figure 4.22). 
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Figure 4.22: The absolute count of total CD8 and VSV-specific CD8 T cells in the 
draining and non-draining lymph nodes after VSV challenge is not affected by 
latent herpesvirus infection. Nine months post herpesvirus (or control) infection, mice 
were challenged with VSV and the absolute number of total CD8 T cells and VSV-
specific CD8 T cells was defined by flow cytometric analysis in an Accuri cytometer. 
Each dot represents a mouse, horizontal lines are medians. Groups were tested by 
Kruskal-Wallis test followed by Dunns post analysis.  
 
4.2.7 Herpesvirus infection does not affect the CD4 T cell response to VSV  
To find out if the CD4 T cell compartment may be affected with any herpesvirus 
infection, this study compared the fraction of CD4 T cell responding to the VSV cell 
lysate by secreting cytokines in mice latently infected with herpesviruses or with control 
non-persisting viruses to the mock-infected control mice. Mock infected lysate was used 
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as the negative control for the stimulation, to assess the amount of TNFα secreting cells 
in absence of antigen-specific responses (Figure 4.23A lower dot plot) and their 
percentage was subtracted from the fraction of CD4 T cells responding to the VSV 
lysate (Figure 4.23A upper dot plot). The following cytokines were tested:  interferon 
gamma (IFNγ), tumor necrosis alpha (TNFα), Interleukin-2, Interleukin 4 and interleukin 
17 responses to lysate stimulation, and only TNFα offered responses that could be 
readily interpreted, whereas all other cytokine responses could not be efficiently 
separated from the background noise (data not shown). Therefore the focus was on 
TNFα responses and CD4 T cell responses were analyzed in both D2B6 and 129B 
strains of mice.  There was no significant difference in the fraction of VSV-specific cells 
neither at day 7 in the peripheral blood nor at day 14 post challenge in the draining 
lymph nodes and spleens of D2B6 mice latently infected with any herpesvirus as 
compared to the control groups (Figure 4.23B, upper panels).  
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Figure 4.23: Herpesviruses do not affect CD4 T cell response to VSV in the D2B6 
mice. (A) Seven and 14 days after the VSV challenge CD4 T cells from the peripheral 
blood and the draining lymph nodes from the D2B6 mice were stimulated with either 
VSV lysate or mock lysate (upper and lower panel respectively) for one hour followed by 
six hours stimulation in the presence of BFA. (B) The fractions of VSV specific CD4 T 
cells from mice previously infected with the herpesviruses (infected for 9 months) were 
compared to the same cells from the peripheral blood of mock infected mice (Kruskal-
Wallis test followed by Dunns post analysis)  
 
Similar results were observed in cells from the peripheral blood and lymph nodes of 
129B mice (Figure 4.24). However, in the blood of 129B mice there was a non-
significant trend towards higher fraction of peripheral VSV specific CD4 T cells from 
mice primed with MCMV, both herpesviruses or flu for 9 months (Figure 4.24 upper 
panels), whereas in D2B6 mice this could be observed in the draining lymph node (LN), 
but not in the blood (Figure 4.23B).  The analysis of absolute response revealed a 
similar, but even more pronounced trend in the blood of the 129B mice but again the 
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difference was not statistically significant (Figure 4.25). Absolute counts of CD4 
responses in D2B6 mice were not assessed due to historical reasons. 
 
Figure 4.24: Herpesviruses do not affect CD4 T cell response to VSV in the 129B 
mice. Seven days after the VSV challenge fractions of VSV specific CD4 T cells from 
129B mice previously infected with herpesviruses were compared to the same cells 
from the peripheral blood and lymph nodes of mock infected mice. Each dot represents 
a mouse (Kruskal-Wallis test followed by Dunns post analysis)  
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Figure 4.25: Herpesviruses do not affect the absolute number of VSV specific CD4 
T cell in the 129B mice. Seven days after the VSV challenge the absolute number of 
VSV specific CD4 T cells from 129B mice previously infected with herpesviruses were 
compared to the same cells from the peripheral blood and lymph nodes of mock 
infected mice. Each dot represents a mouse (Kruskal-Wallis test followed by Dunns post 
analysis)  
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4.2.8 Effects of Herpesvirus infection on the VSV specific neutralizing 
immunoglobulin titer   
VSV can be controlled by neutralizing antibodies produced by plasma cells (138); 
however, in order to mount a protective humoral response, the IgG isotype class switch 
must take place. Therefore, this study also wanted to ascertain the class switch of VSV-
specific antibodies in mice that are latently infected with herpesviruses, and evaluate 
their functional capacity. To this end, sera collected at day seven or fourteen post-VSV 
challenge were used in an in vitro neutralization assay to determine the neutralization 
capacity of VSV specific antibodies. In D2B6 mice there was no significant difference in 
the neutralizing titer of the total Ig (IgG+IgM) serum fraction (Figure 4.26A). The virus-
neutralization capacity of β-mercaptoethanol treated sera was tested. Since β-
mercaptoethanol disrupts the IgM antibodies, these sera contained only the antibodies 
that switched their class. Interestingly, the MCMV-infected group showed a significantly 
lower neutralizing titer in the IgG fraction, as compared to the mock group at day seven 
post challenge. Since this difference could not be observed at day fourteen-post 
challenge (Figure 4.26B), this result suggested a delayed immunoglobulin class switch 
in mice infected with MCMV. 
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Figure 4.26: MCMV infection results in a delayed VSV specific IgG class switch in 
D2B6 mice. (A) Neutralization assay was done using the sera from the D2B6 mice 
challenged with VSV for 7 or 14 days. Serum was pre diluted 40 fold followed by 1:2 
serial dilution steps. (B) The VSV specific immunoglobulin titer was represented as the 
serum dilution at which the number of VSV plaques was reduced by 50%. Each triangle 
represents a mouse and the group with red symbols had a p < 0.05 (Kruskal-Wallis test 
followed by Dunns post analysis).  
 
The same assay was repeated in the 129B strain of mice infected with the primary 
viruses for two weeks, three months or fifteen months prior to the VSV challenge. In 
contrast to the previous experiment, here blood was collected from the mice at days 
four and seven after the VSV challenge, in order to analyze very early responses. In line 
with results from D2B6 mice, the total Ig titer from mice infected with herpesviruses 
showed no difference in neutralizing capacity to the sera from mock-infected mice and 
Serum
VSV
In vitro neutralization assay
A B
IgM/IgG day 7 p.i
MCMVMHV68 HSV1 Triple VACV Mock
0
2
8
10
12
14
Ig
M
/I
g
G
  
ti
te
r 
(-
lo
g
2
x4
0
)
IgG day 7 p.i
MCMVMHV68 HSV1 Triple VACV Mock
0
5
10
15
Ig
G
 t
it
e
r 
(-
lo
g
2
x4
0
)
IgM/IgG day 14 p.i
MCMVMHV68 HSV1 Triple VACV Mock
0
2
4
8
10
12
14
16
Ig
M
/I
g
G
 t
it
e
r 
(-
lo
g
2
x4
0
)
IgG day 14 p.i
MCMVMHV68 HSV1 Triple VACV Mock
0
2
4
8
10
12
14
16
Ig
G
 t
it
e
r 
(-
lo
g
2
x4
0
)
Results 
80 
 
this was the case at either time point (Figure 4.27, 4.28, top panels). Moreover, the IgG 
fraction showed absolutely no VSV neutralization at day four post infection (Figure 4.27, 
lower panels), consistent with the idea that neutralization by class-switched antibodies 
requires more time, but also indicating that VSV-neutralization by β-mercaptoethanol 
treated sera from day 7 and 14 post infection (see Figure 4.26B, right panels) reflected 
the increase in the Ag-specific antibody IgG titer. At day seven post challenge the total 
immunoglobulin in the sera from mice previously infected with viruses was comparable 
to the mock control group, but again there was a trend towards lower IgG responses in 
herpesvirus infected mice. Namely, the VSV specific IgG titer was significantly lower in 
the sera from mice latently infected with the combination of MHV-68 and MCMV (Figure 
4.28) and similar trends, although not significant ones, were observed in other groups 
infected with MCMV alone.   
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Figure 4.27: No difference in neutralizing immunoglobulin titer against VSV at day 
4 post challenge. Serum from the 129B mice primed with MCMV, MHV-68, their 
combination, flu or mock infected for 2 weeks, 3 months or 15 months at the time of 
VSV challenge were collected at day 4 post challenge and used in an in vitro 
neutralization assay. Total immunoglobulin titer (upper panels) or the IgG fraction (lower 
panels) was compared between virus-infected groups and the mock control group. 
Statistical analysis was performed by the Kruskal-Wallis test followed by Dunns post 
analysis. Each triangle represents a mouse, horizontal lines are group medians. The 
data shown here represents pooled data from two independent experiments  
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Figure 4.28: Differences in immunoglobulin titer against VSV at 7 days post 
challenge. Serum from the 129B mice primed with MCMV, MHV-68, their combination, 
flu or mock infected for 2 weeks, 3 months or 15 months at the time of VSV challenge 
were collected at day 7 post challenge and used in an in vitro neutralization assay. Total 
immunoglobulin titer (upper panels) or the IgG fraction (lower panels) was compared 
between virus-infected groups and the mock control group. Statistical analysis was 
performed by the Kruskal-Wallis test followed by Dunns post analysis. Each triangle 
represents a mouse, horizontal lines are group medians. The data shown here 
represents pooled data from two independent experiments  
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Chapter 5 
5.0 Discussion 
This work is intended as a comprehensive study of changes in the homeostasis of the 
adaptive immune system in mice infected with latent herpesviruses. The study provides 
experimental evidence on the effects of latent herpesvirus infection in mice, and of the 
challenge with VSV on the adaptive immune system in homeostasis and in response to 
a new infection. Considering that most people host more than one latent herpesvirus, 
this study addressed also the question, whether multiple infections with herpesviruses 
resulted in additive effects that may have affected the immune homeostasis and the 
adaptive immune response to new infections.    
5.1 Effects of persistent herpesvirus infection on CD8 T cells 
Herpesviruses impact CD8 T cells by permanently increasing the pool of cells with a 
memory phenotype.  Results from this study showed different effects with α, β, or γ 
herpesviruses: MCMV, MHV-68 and the triple infection resulted in an incomplete 
contraction, followed by maintenance of a large EM population after the clearance of the 
acute phase of infection. On the other hand, the HSV-1 infection resulted in a complete, 
but transient contraction of the EM pool, down to levels seen upon the non-persistent 
VACV. This was followed by a second, slowly progressing expansion phase of the EM 
pool.  To my knowledge, no other study has monitored the kinetic of CD8 T cell memory 
subsets in MHV-68 infected mice. However, others have shown that most of EBV-
specific CD8 T cells have a CM phenotype in latently infected individuals, which differs 
from CMV infection, where the majority of cells bear EM phenotype (139, 140). 
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Infections with multiple herpesviruses did not result in significant additive effects on the 
fraction of EM cells in the CD8 pool, as compared to single infection with MCMV or 
MHV-68. These results could mean that the maximum stable size of the CD8 EM 
compartment is achieved in a single-infection already, and hence the cells generated 
against additional herpesviruses cannot add-up to exceed this threshold. The frequency 
of CD8 T cell response to inflationary MCMV peptides was lower in mice infected with 
MHV-68 and HSV-1 prior to MCMV infection, as compared to single infection with 
MCMV. This hypothesis is consistent with the observation that a reduction of HSV-1 
specific responses was not seen in the triple infection, where the HSV-1 infection was 
performed prior to MCMV infection. Alternatively, our results may suggest that the term 
“memory inflation” as it was defined in experimental MCMV infection (75), is a very 
limited term that depends on many factors, including the immune status of the host and 
the history of previous infection with other pathogens. This is supported by the 
observation that germ-free mice infected with MCMV did not exhibit memory inflation, 
but that memory inflation could be initiated when the gut flora was replenished in mice 
carrying latent MCMV (141). Furthermore, another recent study showed that MCMV 
infected mice, injected with a sub-lethal dose of lipopolysaccharides (LPS) during 
latency, displayed a transient contraction of the inflationary CD8 T cells, suggesting that 
pathogen associated molecular patterns or bacterial antigens may also affect the kinetic 
of memory inflation (142). 
MCMV and triple infection resulted in a significant increase in the frequency of CD8 T 
cells expressing NK markers, an effect that was not as pronounced in groups infected 
with other herpesviruses. These results suggest that the changes in the phenotype of 
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CD8 T cells were more prominent in MCMV infection than in infections with other 
herpesviruses. Therefore, it is likely that the effects seen in the group infected with 
multiple viruses was mainly due to the MCMV infection. 
In both strains of mice used in this study, the frequency of peripheral VSV specific CD8 
T cells at day 7 after VSV challenge was lower in mice previously infected with MCMV, 
consistent with our previously published data (79). This was observed in single infection 
or in the infection in combination with other herpesviruses, and it occurred regardless of 
the time-lapse between MCMV infection and VSV challenge. This relative decrease of 
responding cells was in concert with the absolute increase in the number of CD8 T cells 
with EM phenotypes and with the  increase in the count of total CD8 T cells (Figure 
4.12, 4.13, 4.16, and 4.17). Most importantly, there was no difference in the absolute 
number of the VSV specific CD8 T cells in mice infected with any of the herpesviruses 
or in the controls. This was observed in all the tested immune compartments, which was 
consistent with our previous publication, that the count of naïve CD8 cells is not 
decreased in the blood, spleen or lymph nodes of MCMV-infected mice (79). These 
results strongly suggest that the absolute number of CD8 T cells generated against new 
pathogens is relatively similar, regardless of the history of herpesvirus infection. MCMV 
infection was the only infection that significantly increased the total CD8 T cell count. A 
recent publication by Mekker et al., showed that MCMV infected mice had increased 
peripheral CD8 T cell counts and that the effect was more pronounced in the 
thymectomized mice. Moreover, upon challenge with lymphocytic choriomeningitis virus 
(LCMV), the absolute number of LCMV specific CD8 T cell from the lungs and spleen of 
MCMV and mock-infected mice was similar (49). Therefore, previous interpretations of 
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data from MCMV-infected mice, which showed a decrease in the percentage of CD8 T 
cells responding to a new infection (79, 143) need to be revised, in order to consider the 
difference in the total number of CD8 T cells that exists between CMV-infected and non-
infected groups. 
The expansion of the peripheral EM CD8 T cell pool in mice infected with 
herpesviruses, and in particular with MCMV, led us to speculate that this might interfere 
with the activation of new T cells in the draining lymph nodes (79). Guarda et al., have 
shown that pre-existing EM CD8 T cells (CD62L and CCR7 negative), have the 
potential to enter draining lymph node through high endothelial venules, mainly due to 
their expression of CXCR3 during an acute response to Listeria monocytogenes 
challenge (144). A model that considered that the numbers of naïve T cells in CMV 
infected and uninfected mice are similar, but that the EM CD8 T cells might obstruct the 
activation of naïve cells in the draining lymph node of CMV infected mice was proposed 
(Figure 5.1A and 5.1B). 
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Figure 5.1: Proposed models for CD8 T cells activation in the draining lymph 
nodes  
 
This hypothesis was tested by analyzing the frequency and absolute numbers of VSV 
specific CD8 T cells in the draining and non-draining lymphoid organs (spleen and 
lymph nodes). There was higher number of antigen-specific cells in the draining than in 
the non-draining lymph nodes suggesting that the activation of CD8 T cells in the 
draining lymph node was efficient. However, a comparable number of these cells in the 
lymph nodes of mice infected with herpesviruses and in the control groups was 
observed, refuting the model from the original hypothesis (Figure 5.1B) and supporting 
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a model where the increase in the memory cells does not impair the ability of the naïve 
cell compartment to mount an antigen-specific response (Figure 5.1C). These results 
were consistent with the observations of Torti et al., who showed that the inflation of 
CD8 T cells in the peripheral pool of CMV infected mice depends on the continuous 
activation of CD8 T cells by  latently infected non-hematopoietic cells (145). Therefore, 
their data argued that memory inflation in latent MCMV infection is not a result of T-cell 
stimulation by professional APCs in the lymph nodes, which would be consistent with 
our observation that herpesviruses did not impact the activation of VSV-specific CD8 T 
cells in the lymph nodes. 
Our results strongly suggest that infection with a herpesvirus and the consequent 
memory inflation do not affect the absolute number of VSV specific T cells, despite the 
homeostatic changes observed in the CD8 T cell compartment. Several groups have 
proposed to use CMV as a vector to develop T cell-based vaccines (146-149). 
Importantly, the insertion of additional antigen in CMV-based vaccine vectors does not 
alter the size of the CMV specific CD8 response, because the EM CD8 T cells specific 
for the inserted antigen displaces the responses to intrinsic antigens present in the CMV 
genome (124). We recently published that MCMV infection results in lower frequencies 
of CTL responses to emerging pathogens (79), thus raising concerns that CMV-based 
vaccine vectors may have iatrogenic potential, because they may impair the ability of 
the immune system to protect against environmental pathogens. However, the results 
shown in this thesis indicate that vaccination with viable CMV vectors would not impair 
immune system in its ability to respond to emerging infections, and alleviates the 
concerns about their iatrogenic potential. 
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5.2 Effects of persistent herpesvirus infection on CD4 T cells 
Our results showed that the infection with a single herpesvirus does not have a 
significant effect on the fraction of EM CD4 T cells unless the mice were infected with a 
combination of all three herpesviruses used in our study. This suggests that multiple 
infections with herpesviruses might have an additive effect on CD4 T cell homeostatic 
changes, in stark contrast with the changes seen in the CD8 T cell compartment. 
There was a significantly reduced frequency of regulatory T cells (Tregs) in the MHV-68 
group as compared to the control groups and a similar, but non-significant trend in the 
frequency and absolute numbers was observed in other herpesvirus groups. This may 
indicate that herpesvirus infection results in a slight reduction in the Tregs populations 
as an immune strategy to enhance EM CD8 T cell proliferation and pro-inflammatory 
cytokine production, thus keeping the latent virus in check. This is supported by 
previous in vitro studies that showed that the depletion of Tregs enhances the function 
and proliferation capacity of virus specific CD8 T cells (150-152), in line with the well-
known immunosuppressive function of Tregs (25). Similarly, MCMV infection of IL10 
deficient mice showed a reduced latent MCMV genome which suggested an enhanced 
viral control by the proinflamatory cytokines (133). Future studies of the effect of 
adoptive transfer of Tregs into mice infected with latent herpesviruses may prove the 
validity of this hypothesis. 
While Th1 CD4 T cells have the potential to control virus replication, there was no 
significant difference in the fraction or the absolute numbers of VSV specific CD4 T cells 
responding with Th1 cytokines. This was the case both in the peripheral blood and in 
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the lymph nodes of mice that have been infected with herpesviruses, implying that Th1 
responses against new infections were not affected by the latent herpesviruses. 
5.3 Effects of persistent herpesvirus infection on B cells 
The fractions of memory B cells were comparable between mice infected for eight 
months with herpesviruses and control groups. Therefore, our data suggest that the 
homeostasis of B cells may not be affected by lifelong herpesvirus infection (Figure 4.9). 
On the other hand, CMV-infected D2B6 mice mounted significantly lower VSV 
neutralizing titers in the IgG fraction of antibodies at day seven post VSV challenge but 
not after 14 days, suggesting a delayed Ig class switch (Figure 4.26). Double infected 
group (MCMV and MHV-68) 129B mice also had low VSV specific IgG titer (Figure 
4.28). These data suggest that MCMV infection in isolation or in combination with other 
herpesviruses may affect primary humoral responses to new infections namely by 
delaying the Ig class switch. Neutralizing antibody titers produced by plasma cells 
depends on help from follicular CD4 T cells that facilitate Ig class switch. Recent data 
from a human study showed that CMV antibody titers correlate directly with the 
frequency of EM CD4 T cells and impair influenza-specific IgG responses upon 
vaccination (153). Our data showed that multiple herpesvirus infections have an additive 
effect on the frequency of EM cells in the CD4 compartment (Figure 4.7), which 
provided a plausible explanation for the delay of the Ig class-switch. On the other hand, 
the CD4 T-cell response to VSV was not impaired in herpesvirus infection, arguing that 
the class-switch delay was caused by changes that were intrinsic to the B cell 
compartment. Further studies are needed to find out the exact mechanism and 
consequences of the class switch delay, as well as the exact IgG class that is 
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predominantly induced upon VSV challenge of latently infected mice. Another 
interesting question that may be addressed in future studies is whether recall responses 
would also be delayed.  
In general, data from this study indicate that herpesvirus infections impact the T and B 
cell compartment (Table 5.1), but that the effect in the B cell compartment was mainly 
on the neutralizing antibody titer, and not on the maintenance of peripheral memory 
populations. There was a significant reduction of the survival rate in the MCMV infected 
group; however, this occurred in one experiment only and was not recapitulated in the 
triple-infection group in the same experiment suggesting this might be a random event 
not related to CMV infection.   
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Table 5.1: summarized effects of long life herpesvirus infection on the adaptive 
immunity   
Adaptive immunity 
Alpha- 
herpesvirus 
(HSV-1) 
Beta-
herpesvirus 
(MCMV) 
Gamma-
herpesvirus 
(MHV-68) 
Combination 
(triple/double) 
Changes in the 
homeostasis of peripheral 
CD8 T cells 
++ +++ ++ +++ 
Frequency of  peripheral 
CD8 T cells responding to 
a new infection 
+ ++ + ++ 
Absolute number of 
peripheral  CD8 T cells 
responding to a new 
infection 
- - - - 
Total peripheral  CD8 T 
cells  
+ +++ + +++ 
Homeostasis of peripheral 
CD4 T cells 
+ + + ++ 
Peripheral CD4 response 
to a new infection 
- - - - 
T cells response in the 
lymphoid organs 
- - - - 
Homeostasis of peripheral 
B cells 
- - - - 
Antibody response to a 
new infection 
- ++ - ++ 
 
+++ showed a highly significant impact relative to the mock group 
++ showed significant impact relative to the mock group 
+ showed borderline significant or a not significant trend relative to the mock group 
-  showed no obvious impact  
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Chapter 6 
6.0 Conclusions and recommendations for future studies 
Data from this study show that herpesvirus infections result in permanent changes of 
the homeostasis but not of the function of CD4 and CD8 T cells, measured as the ability 
to respond to a new infection. While previously published data have indicated that the 
abundance of MCMV-specific CD8 T cells in latently infected mice might impair the 
response to a neo-antigen in the aged hosts (8, 49, 79), the data presented here show 
that only the fraction of peripheral VSV specific CD8 T cells but not their absolute 
number was significantly reduced in mice bearing latent MCMV. Likewise, there was no 
significant difference in the fraction of lymph node-derived CD8 or CD4 T cells 
responding to VSV antigen in any mouse group. Therefore, this study argues that 
herpesvirus infections do not impair the function of the immune system relative to its 
ability to respond to and protect against an emerging viral challenge. While our data 
alleviate concerns about the pathogenic potential of natural CMV infection, they also 
support future prospects of using CMV as a vector to develop T cell-based vaccines. 
Follow-up studies are needed to clarify if the expansion of EM CD8 T cells caused by 
CMV infection results in an increase of chronic inflammatory conditions in latently 
infected hosts. 
Finally, this study showed that long-term infection with herpesviruses does not affect the 
fraction of memory B cells, but the VSV challenge revealed a significant delay in the 
class switch of VSV-neutralizing antibodies in mice latently infected with MCMV. Future 
studies should determine whether this delay in the class-switch may also impair the 
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immune control of emerging pathogens in latently infected hosts, and if the 
phenomenon is mouse-specific or may be translated to the human situation as well.  
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